Inflammation biomarkers, including higher high-sensitivity C-reactive protein (hsCRP) levels, higher white blood cell (WBC) counts, and lower serum albumin levels, are associated with an increased risk of all-cause mortality. Many studies have examined these biomarkers individually, but less is known about their joint association with mortality. hsCRP, WBC count, and serum albumin were measured at baseline in the Reasons for Geographic and Racial Differences in Stroke Study cohort members, who were enrolled in 2003-2007. Over 4.5 years, there were 1,062 deaths in 17,845 participants. High-risk categories were defined as hsCRP or WBC levels above the 75th percentile (5.1 mg/L and 6.9 3 10 9 cells/L, respectively) and albumin levels below the 25th percentile (4.00 g/dL). The authors derived 4 groups that corresponded to 0 (n ¼ 8,341), 1 (n ¼ 6,277), 2 (n ¼ 2,635), or 3 (n ¼ 592) biomarkers in the high-risk category. After adjustment for age, sex, waist circumference, race, region, smoking, alcohol use, income, educational level, physical activity frequency, and medical history and compared with those with no biomarkers in the high-risk category, the hazard ratios for all-cause mortality for 1, 2, and 3 biomarkers in the high-risk category were 1.56 (95% confidence interval: 1.33, 1.82), 2.19 (95% confidence interval: 1.84, 2.62), and 2.96 (95% confidence interval: 2.30, 3.80), respectively (P trend < 0.0001). Adding the 3 inflammation biomarkers to a fully adjusted model improved risk discrimination by 23.7% (95% confidence interval: 9.3, 39.9). Measurement of more than 1 biomarker is more useful in risk prediction than single biomarkers.
Inflammation biomarkers, including higher concentrations of high-sensitivity C-reactive protein (hsCRP), higher white blood cell (WBC) counts, and lower serum albumin levels, are individually associated with increased risk of cardiovascular disease (CVD) and all-cause mortality (1) (2) (3) (4) (5) (6) . Researchers who have conducted studies (3, (7) (8) (9) to investigate inflammation biomarkers in combination have found that the risks of CVD and all-cause mortality are higher when more than 1 biomarker is outside of the normal range. Serum albumin is lower and both hsCRP and WBC count are higher with increasing body fat (3, 8, 10) . All 3 biomarkers vary by sex and race (11) (12) (13) and are strongly associated with mortality (14, 15) . WBC counts are generally lower in blacks than in whites, but the clinical significance of this is not known (12, 13) .
Although high hsCRP level and WBC count and low serum albumin level are independent risk factors for CVD and allcause mortality (1, 3, 4) , data on the joint association between these biomarkers and all-cause mortality in diverse populations are scant. Further, how the joint effects of inflammation biomarkers on mortality might be modified by correlates of inflammation, such as central obesity, sex, and race, is not known.
The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study, which included data on mortality rates, some biomarkers of inflammation, and potential confounders, offers a unique opportunity to test whether the risk of all-cause mortality increases with an increase in the number of biomarkers in categories associated with increased risk of mortality and whether this association is modified by factors that correlate with inflammation.
MATERIALS AND METHODS
From January 2003 to October 2007, the REGARDS Study investigators enrolled 30,239 black and white individuals 45 years of age or older from across the continental United States, with oversampling of blacks and persons from the "stroke belt" region of the United States, an 8-state (North Carolina, South Carolina, Georgia, Tennessee, Mississippi, Alabama, Louisiana, and Arkansas) area with a higher stroke mortality rate than the rest of the United States. The study design has been described elsewhere (16) . Briefly, potential participants were invited to participate by mail and telephone, and those who consented were interviewed via telephone to collect demographic and risk-factor data. An in-home visit was then completed using standardized protocols to obtain blood samples and information on measured risk factors, such as blood pressure, height, weight, and waist circumference. Individuals or their proxies were followed using twice-yearly telephone calls to monitor the development of stroke and other outcomes, including death. A protocol for resolving potential lost participants was implemented for anyone who missed 3 or more consecutive follow-up telephone contact attempts. If a death was reported or discovered through database searches, death certificates were sought to confirm the death, and interviews with next of kin or proxies were conducted to confirm the death event and the date of death.
Laboratory analyses
Blood samples were collected after a 10-to 12-hour fast, centrifuged locally, and shipped to a central laboratory at the University of Vermont for reprocessing and analysis. hsCRP was measured using particle-enhanced immunonephelometry (N High-Sensitivity CRP assay; Dade Behring, Inc., Deerfield, Illinois) (17) . WBC count was measured using an automated analyzer (Beckman Coulter, Inc., Fullerton, California) (18) . Lipid profiles and albumin and glucose levels were measured using standard clinical assays (19) . The interassay coefficients of variance were 2.1%-5.7% for hsCRP, 5% for WBC count, and <5% for albumin. Albumin and WBC count were measured only among 21,658 consecutive individuals in an ancillary study that began after enrollment for the main study had started (18) .
Definitions
All-cause mortality was the outcome. The number of inflammation biomarkers in the extreme categories associated with increased risk of mortality was the main exposure. We defined high-risk categories of each biomarker as hsCRP or WBC levels above the 75th percentile (5.1 mg/L and 6.9 3 10 9 cells/L, respectively), or an albumin level below the 25th percentile (4.00 g/dL). Four mutually exclusive a priori risk groups were used to classify each participant by the number of inflammation biomarkers in the high-risk category at baseline: 0 (n ¼ 8,341), 1 (n ¼ 6,277), 2 (n ¼ 2,635), or 3 (n ¼ 592).
Covariates
Important covariates included age, sex, self-reported race (black vs. white), region (stroke buckle (North Carolina, South Carolina, and Georgia), rest of the stroke belt, or other), smoking status, waist circumference, alcohol use, annual household income, educational level, high density lipoprotein (HDL) cholesterol level, low density lipoprotein (LDL) cholesterol level, triglyceride level, frequency of physical activity, diabetes, hypertension, stroke, coronary heart disease (CHD), heart failure, chronic kidney disease, and use of statins. History of CHD was defined as any selfreported myocardial infarction/heart attack, coronary artery bypass surgery, coronary angioplasty/stenting, or evidence of a myocardial infarction from an electrocardiogram. Diabetes was defined as a fasting glucose level greater than 126 mg/dL, a nonfasting glucose level greater than 200 mg/dL, or self-reported medication use for glucose control. Hypertension was defined as a systolic blood pressure of 140 mm Hg or higher, a diastolic blood pressure of 90 mm Hg or higher, or self-reported use of antihypertensive medication. Patients were categorized by smoking status as never smokers, former smokers, or current smokers. Alcohol consumption was categorized as none, moderate (i.e., between 1 drink/week and no more than 2 drinks/day), or heavy (>2 drinks/day). Annual household income was modeled in 5 categories: less than $20,000, $20,000-$34,000, $35,000-$74,000, $75,000 or more, or refused to disclose. Educational level was modeled in 4 categories: college graduate or above, some college, high school graduate, or less than high school. Reported frequency of physical activity was modeled in 3 categories: none, 1-3 times per week, and 4 or more times per week. Diabetes, hypertension, stroke, CHD, heart failure, chronic kidney disease, and use of statins were modeled as binary variables.
Statistical analysis
Of the 30,239 individuals in the REGARDS cohort, we excluded 10,574 participants because of missing data on inflammation biomarkers (n ¼ 8,730 for WBCs, n ¼ 1,830 for hsCRP, and n ¼ 14 for albumin), 388 because of missing follow-up information, and 1,432 because of missing data on key covariates, including smoking status, annual income, educational level, diabetes, hypertension, HDL level, LDL level, triglyceride level, or waist circumference, which resulted in an analysis cohort of 17,845 participants (62% women, 60% white). Of the individuals for whom we had complete data, 1,062 died during follow-up. Continuous variables were checked for normality, and skewed variables (i.e., hsCRP, WBC, and triglyceride levels) were log-transformed to normalize their distributions. To identify potential confounders, we compared the distribution of risk factors across categories of the exposure variable, which was the number of inflammation biomarkers in the quartile associated with an increased risk of all-cause mortality. We also examined the distribution of the risk factors by quartiles of hsCRP, serum albumin, and WBC count, as shown in Web Tables 1-3 (available at http://aje.oxfordjournals.org/). The significance of the differences across exposure groups was tested using the chi-squared test for categorical variables and analysis of variance for continuous variables.
We fitted Kaplan-Meier survival curves for all-cause mortality for individuals with 0, 1, 2, or 3 inflammation biomarkers in the quartile associated with increased risk of allcause mortality and used the log-rank test to determine the significance of the differences in mortality rates among groups. We used Cox proportional hazards models to test whether the number of inflammation biomarkers in the high-risk category was associated with risk of all-cause mortality. Interactions between the number of inflammation biomarkers in the high-risk categories and race, sex, and waist circumference were tested for statistical significance in Cox regression analyses in which we used cross-product terms.
In additional analyses, cross-products of inflammation biomarkers as continuous variables and race, sex, and waist circumference were used to test for interactions because this would yield higher statistical power for the interactions. If race, sex, or waist circumference showed a significant interaction with the number of inflammation biomarkers or with individual inflammation biomarkers, we performed stratified analyses by that variable. To estimate the risk of all-cause mortality associated with a 1-standard-deviation increase in a given inflammation biomarker, we divided each biomarker by its standard deviation and added the resulting variables to the model that also included interaction terms of all 3 biomarkers with race.
In sensitivity analyses, we derived race-and sex-specific cutpoints of the inflammation biomarkers (i.e., hsCRP or WBC levels above the 75th percentile or albumin levels below the 25th percentile in a given sex and race stratum) to test whether the number of biomarkers in the abnormal range based on sex-and race-specific distributions had a different association with all-cause mortality compared with the initial analyses. In addition, we performed analyses after excluding individuals with hsCRP values of 10 mg/L or higher so as to reduce the potential effect of an ongoing infection on the hsCRP values. All tests for main effects and interactions were considered statistically significant at P 0.05. Results are reported as hazard ratios and 95% confidence intervals.
To determine whether including inflammation biomarkers in the model that was fully adjusted for various risk factors for mortality improved risk discrimination, we estimated the relative integrated discrimination improvement and corresponding bootstrap 95% confidence intervals (20) . The variables in the fully adjusted model were age, sex, smoking status, waist circumference, race, region, alcohol use, income, educational level, HDL level, LDL level, triglyceride level, physical activity frequency, diabetes, hypertension, stroke, CHD, heart failure, chronic kidney disease, and use of statins. We computed the relative integrated discrimination improvement after adding hsCRP, WBC, and albumin levels simultaneously to the fully adjusted model. We repeated the analyses after excluding WBC count or albumin or any 2 of the 3 biomarkers from the model to assess the change in risk discrimination attributable to a given inflammation biomarker.
RESULTS
Over a median follow-up period of 4.52 years (range, 0.12-7.53 years), 1,062 of the 17,845 participants died. Table 1 shows the characteristics of the study population by number of inflammation biomarkers in the high-risk category. Age, body mass index (weight in kilograms divided by height in meters squared), waist circumference, triglyceride level, and the proportions of women, prevalent CHD, stroke, diabetes, heart failure, chronic kidney disease, and current smokers were all greater in categories with a higher number of biomarkers in the high-risk category (all P's < 0.0001), whereas higher educational level, current alcohol drinking, physical activity frequency, HDL and LDL cholesterol levels, and proportion of whites were lower with an increasing number of inflammation biomarkers in the high-risk category. In addition, we examined the distribution of various risk factors in Table 1 across quartiles of hsCRP (Web Table 1 ), WBC count (Web Table 2 ), and albumin (Web Table 3 ). These distributions were essentially similar to trends seen in Table 1 . Figure 1 shows the Kaplan-Meier survival curves for individuals with 0, 1, 2, or 3 inflammation biomarkers in the high-risk category. The mortality rate (38.7 per 1,000 person-years; 95% confidence interval (CI): 31.6, 47.4) was highest among individuals with 3 inflammation biomarkers in the high-risk category (log-rank test: P < 0.0001). Mortality rates per 1,000 person-years for individuals with 0, 1, and 2 inflammation biomarkers in the high-risk category were 8.2 (95% CI: 7.3, 9.2), 15.3 (95% CI: 13.9, 16.9), and 24.3 (95% CI: 21.6, 27.4), respectively. Similar results were obtained when race-and sex-specific cutpoints were used to define biomarkers in the high-risk category (data not shown). Table 2 shows results from multivariable analyses. Compared with persons without biomarkers in the high-risk category, individuals with 1, 2, and 3 biomarkers in the high-risk category had hazard ratios of 1.56 (95% CI: 1.33, 1.82), 2.19 (95% CI: 1.84, 2.62), and 2.96 (95% CI: 2.30, 3.80), respectively (P trend < 0.0001), after adjustment for baseline age, sex, waist circumference, race, region, smoking, alcohol use, income, educational level, lipid level, frequency of physical activity, diabetes, stroke, CHD, heart failure, chronic kidney disease, and use of statins. Similar results were obtained when the number of biomarkers in the high-risk category was defined based on sex-and racespecific distributions (data not shown). In relation to mortality risk, there were no statistically significant interactions between the number of inflammation biomarkers in the highrisk category and race, waist circumference, or sex (P > 0.05).
Albumin level was poorly correlated with WBC count (r ¼ 0.01, P = 0.35), whereas hsCRP level was modestly correlated with WBC count (r ¼ 0.25, P < 0.0001) and albumin level (r ¼ À0.21, P < 0.0001). Thus, albumin level, WBC count, and hsCRP level were modeled together as continuous variables. In an analysis adjusted for all covariates in Table 2 and with hsCRP, WBC, serum albumin level, and their 2-way interactions in the model as continuous variables, hsCRP (P ¼ 0.01) and albumin (P ¼ 0.001) main effects and the WBC 3 hsCRP (P ¼ 0.02) and hsCRP 3 albumin (P ¼ 0.03) interactions were significantly associated with all-cause mortality. The WBC main effect (P ¼ 0.10) and the WBC 3 albumin interaction (P ¼ 0.08) were not significantly associated with all-cause mortality.
Next, we standardized hsCRP, WBC count, and serum albumin level by dividing them by their respective standard deviations. We then entered the standardized variables into the model as continuous variables together with race and the interaction terms of those variables and race, a binary variable, to estimate the risk of all-cause mortality associated with a 1-standard-deviation increase in a given biomarker. In the fully adjusted model (the model that included all covariates in Table 2 ), the risk of mortality associated with a 1-standarddeviation increase in hsCRP was 1.33 (95% CI: 1.22, 1.45), whereas it was 1.20 (95% CI: 1.10, 1.31) for an increase in WBC count and 0.81 (95% CI: 0.74, 0.89) for an increase in serum albumin. In this model, the race 3 inflammation-biomarker interaction terms were significant (P ¼ 0.04 for hsCRP, P ¼ 0.01 for albumin, and P ¼ 0.05 for WBC).
WBC counts in black men are known to be lower than those in white men (12) . We performed analyses of the relation between WBC count and all-cause mortality after stratifying by race. Results from analyses with race-specific quartiles of WBC count are shown in Table 3 . In both blacks and whites, models adjusted for age, sex, and smoking status showed that an increase in WBC count was associated with an increase in the all-cause mortality rate. However, after adjustment for various risk factors for mortality (Table 3) , the association remained significant only among whites. In the fully adjusted model, the hazard ratio for the fourth quartile of WBC count versus the first was 1.33 (95% CI: 1.03, 1.72) in whites and 1.13 (95% CI: 0.86, 1.50) in blacks.
Relative integrated discrimination improvement
Compared with the fully adjusted model, a model that included hsCRP, WBC, and albumin level as continuous variables improved risk discrimination by 23.7% (95% CI: 9.3, 39.9). When WBC count was included in the model, the addition of hsCRP and albumin data improved risk discrimination by 20.6% (95% CI: 6.6, 36.2). Addition of WBC and albumin data to the model that included hsCRP improved risk discrimination by 11.5% (95% CI: À1.1, 26.2). When albumin was included in the model, the Abbreviations: CI, confidence interval; HR, hazard ratio. a We defined high-risk categories of each biomarker as a high-sensitivity C-reactive protein level or white blood cell count higher than the 75th percentile (5.1 mg/L and 6.9 3 10 9 cells/L, respectively) or a serum albumin level below the 25th percentile (4.00 g/dL). b Model 1 was the unadjusted model. Model 2 was adjusted for baseline age, sex, and smoking status. Model 3 was adjusted for the variables in model 2 and baseline waist circumference, race, region, alcohol use, income, educational level, high density lipoprotein level, low density lipoprotein level, triglyceride level, physical activity frequency, diabetes, hypertension, stroke, and coronary heart disease. Model 4 was adjusted for the variables in models 2 and 3, as well as heart failure and chronic kidney disease. Model 5 was adjusted for the variables in models 2, 3, and 4, as well as use of statins.
addition of hsCRP and WBC data improved risk discrimination by 7.3% (95% CI: À5.2, 21.3).
DISCUSSION
In the REGARDS cohort, the risk of all-cause mortality increased proportionally to the number of inflammation biomarkers in the quartile associated with increased risk of mortality (i.e., the high-risk category). This association did not differ by race, sex, or waist circumference and was not sensitive to racial or sex differences in the distributions of the biomarkers. Although the number of inflammation biomarkers in the high-risk category did not show a significant interaction with race, the interaction between WBC count and race was significant in models with all-cause mortality as an outcome. Our analyses confirmed results from previous studies (1, 3, 5) that showed that hsCRP and WBC count are positively associated, whereas albumin is inversely associated, with all-cause mortality, independent of known risk factors. Our findings agree with and extend findings from other studies (3, 7, 8) that showed that mortality risk is higher when 2 or more inflammation biomarkers are in a range associated with increased risk of mortality.
Much of the focus on biomarker use in clinical medicine has been on hsCRP as a cardiovascular risk biomarker. However, hsCRP is also related to non-CVD mortality (6) , and other inflammation biomarkers have also been shown to be associated with mortality and chronic diseases, such as CVD and diabetes (8, 9, 21) . Risk discrimination, as measured by the relative integrated discrimination improvement metric, showed that adding data on 3 inflammation biomarkers to Abbreviations: CI, confidence interval; HR, hazard ratio. a Model 1 was adjusted for baseline age, sex, and smoking status. Model 2 was adjusted for the variables in model 1 and baseline waist circumference, race, alcohol use, income, educational level, high density lipoprotein level, low density lipoprotein level, triglyceride level, physical activity frequency, diabetes, hypertension, stroke, and coronary heart disease. Model 3 was adjusted for the variables in models 1 and 2, as well as high-sensitivity C-reactive protein and serum albumin as continuous variables. Model 4 was adjusted for the variables in models 1, 2, and 3, as well as statin use, heart failure, and chronic kidney disease. In this model, the HR for all-cause mortality associated with a 1-log increase in highsensitivity C-reactive protein was 1.13 (95% CI: 1.04, 1.22) in blacks and 1.28 (95% CI: 1.18, 1.38) in whites. In the same model, the HR for a 1-g/dL increase in albumin was 0.30 (95% CI: 0.23, 0.40) in blacks and 0.55 (95% CI: 0.42, 0.72) in whites.
the model with standard risk factors for mortality improved risk discrimination by 23.7%. Our findings are important in that they show the potential value of using 2 or more inflammation biomarkers to identify individuals at greater risk of all-cause mortality and that they are in agreement with other studies which showed that inflammation biomarkers are related to CVD and non-CVD mortality rates (6).
Although we did not demonstrate significant differences between number of inflammation biomarkers in the high-risk category and risk of all-cause mortality in important subgroups (race, sex, and central obesity), the association between WBC count and all-cause mortality was significant among whites (hazard ratio for the fourth quartile vs. the first quartile ¼ 1.33, 95% CI: 1.03, 1.72) but not in blacks (hazard ratio for the fourth quartile vs. the first quartile ¼ 1.13, 95% CI: 0.86, 1.50), despite the large number of deaths and large sample sizes in each group (Table 3 ). The lack of a significant association between WBC count and all-cause mortality in blacks may be due to the high prevalence of benign ethnic neutropenia (12, 13) and suggests that WBC types may be more etiologically relevant for predicting mortality than the total WBC count in blacks. Further, WBC count might not be a good biomarker for all-cause mortality in blacks because a suggestion of increased mortality risk was observed only at higher WBC counts (Table 3) .
Our study had some limitations. We used self-reported race, which varies in the degree of racial admixture. We included only the 3 inflammation biomarkers that were already available in the REGARDS Study database, and we did not adjust for or exclude individuals because of conditions and medications that could have affected concentrations of inflammation biomarkers (e.g., use of fibrates) (22, 23) . However, adjustment for use of statins, a group of medications with a strong effect on inflammation (24) , only marginally attenuated the association between inflammation biomarkers and all-cause mortality, and this association remained significant ( Table 2) . Exclusion of individuals with a hsCRP level of 10 mg/L or higher did not change the associations appreciably. We also do not yet have classification of cause of death for analysis. It is possible that inflammation biomarkers may have different associations with different causes of death. Nonetheless, our study had a number of strengths, including the large sample of blacks and whites from the entire continental United States, assays performed in one central laboratory with an interassay variability below 6%, direct measurement of important risk factors, and use of trained examiners and interviewers and frequent follow-up to minimize loss to follow-up. Furthermore, we accrued a large number of deaths (n ¼ 1,062) over a median 4.5 years of follow-up, which gave us ample statistical power for the analyses.
Levels of inflammation biomarkers add to each other in determining risk of all-cause mortality. As shown by the relative integrated discrimination improvement metric, measurement of more than one biomarker may be more useful than measurement of a single biomarker for this purpose. WBC count was associated with increased risk of all-cause mortality among whites but not among blacks. Further analysis is needed to address clinical implications of this observation.
